Shots:
- The companies plan to leverage TenNor’s multitargeting drug conjugation platform to discover new therapies for NTM diseases. The agreement was facilitated by J&J
- The focus of the pact to discover and develop novel therapies for NTM diseases with the potential to shorten the duration of treatment with better safety and efficacy
- The collaboration builds on the scientific know-how and background IP of TenNor associated with its drug conjugation technology. The collaboration will integrate companies’ expertise together to discover new treatment modalities for NTM diseases
Click here to read full press release/ article | Ref: PRNewswire | Image: Web24 News
The post Janssen Signs a Research Agreement with TenNor to Develop Treatments for Nontuberculous Mycobacteria Diseases first appeared on PharmaShots.
